SELECTBIO - NanoPharmaceuticals Keynote Speakers

Home

Agenda

Keynote Speakers

Register

Exhibition

Venue

Ahmed Faheem

Senior Lecturer in Pharmaceutics, University of Sunderland

Sorry, There is currently no biography for this presenter.

Kewal Jain

Chief Executive Officer/Professor, Jain Pharma Biotech

Professor K. K. Jain is a neurologist/neurosurgeon by training with fellowship qualifications from the Royal Colleges of Surgeons in Canada and Australia. After his retirement from clinical practice, he has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech.
Prof. Jain’s 455 publications include 25 books (5 as editor + 20 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. His important recent books include "Handbook of Nanomedicine" (Springer 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012) and Textbook of Peronalized Medicine, 1st ed 2009; Japanese edition 2012, 2nd ed Springer, 2015.

Jagat Kanwar

Professor, Deakin University

Professor Jagat Kanwar is group leader and head of the Nanomedicine and Laboratory of Immunology and Molecular Biomedical Research has an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases. We also vested the molecular diagnosis including role of a non-invasive exosomes in blood, inflammatory sites and cancer tissues. Our research focused on cancer and inflammatory autoimmune diseases aims to investigate the underlying mechanisms involved in apoptosis, autophagy and inflammation by targeting the production of cytokines, chemokines, oxygen radicals and matrix metalloproteinase. Our research also aims to investigate the nanotherapeutics encapsulating peptides, LNA modified aptamers/miRNAs/siRNA in vivo models. We have made significant progress in field of ocular drug delivery and microfluidic and Lab-on-a-Chip devices techniques for cancer cells as well as stem cell capture, disease specific biomarkers and exosomes. His publications more than 150 research papers and have added to the body of knowledge in the fields of nanobiotechnology, cancer gene therapy, cell biology and immunology. Kanwar's research work has generated a total of 12 patent/PCTs. He is the member of various scientific committees and societies.

Samuel M Lawrence

CEO, Cytoviva Inc

Mr Samuel M. Lawrence is the Chief Executive Officer and a Co-Founder of CytoViva, Inc., based in Auburn, AL. Mr. Lawrence led the development of the core, patented illumination technology which is the foundation for CytoViva’s products. He continues to lead all product development efforts as well as actively support the company’s sales efforts both domestically and internationally. Mr. Lawrence is also the CEO of Aetos Technologies, Inc., a technology development company located in Auburn, AL.

Prior to CytoViva, Mr. Lawrence was a Director at Boeing Commercial Airplanes in Seattle, WA where he led Supply Chain Transformation for the 737/757 Programs and was Factory Manager of the Interiors Responsibility Center. Prior to Boeing, Mr. Lawrence worked with Deloitte & Touche, LLC as a management consultant. Mr. Lawrence began his career in 1986 as an engineer on the Boeing Commercial Airplanes Aerodynamics Staff after graduating from Mississippi State University with a Bachelor of Science degree in Aerospace Engineering. He is co-inventor on two U.S. Patents for his work on innovative insulation materials for commercial airplanes. Mr. Lawrence left Boeing in 1991 to continue his education at the Northwestern University Kellogg Graduate School of Management where he earned a Masters of Management in Manufacturing in 1993. Mr. Lawrence also completed the International Executive Programme at INSEAD (Fontainebleau, France/Singapore) in 2002. In 2011 he was named a Distinguished Engineering Fellow at Mississippi State University and in 2014 he was admitted to the Auburn University chapter of the National Academy of Inventors.

Manika Pal Bhadra

Principal Scientist, Indian Institute of Chemical Technology

Dr. Manika Pal Bhadra is an eminent and one of the well reputed scientists in India. She is presently working as a principal scientist and Head of the division Centre for Chemical Biology at CSIR-Indian Institute of Chemical Technology, Hyderabad. She was awarded Ph. D in the area of Adv. Cytology and Mol. Genetics from Calcutta University, India and Post Doctorial studies at University of Missouri, Columbia. She has 96 research publications in international Journals like Cell, Science, Molecular Cell, Gene, Nature Genetics, Nanotechnology etc. in the areas of RNAi & Epigenetic, Nanotechnology and Drug discovery. She is currently handling various in-house and international projects which include i) Role Of RNAi on heterochromatin silencing and its assembly in Drosophila. ii) Screening and development of novel drug targets that act as histone deacetylases inhibitors iii) Development and biological evaluation of nanoparticles for targeted delivery of siRNA to cells. iv) Screening of biological evaluation of small molecule modifiers of micro RNA. She is recipient of several prestigious awards like Nasi Reliance-2012, Wellcome Trust Fellow-2005, IICT Best Women Scientist-2012, IICT Roll of Honour-2007 and Young Scientist Award-1991 to her credit.

Mandip S Sachdeva

Professor, Florida A&M University

Dr Mandip Sachdeva, PhD, a professor and section leader for the pharmaceutics activity in the College of Pharmacy and Pharmaceutical sciences, has secured more $ 25 million in grant. His work has resulted in more than 90 peer reviewed publications, six book chapters and more than 150 presentations in national and international meetings.He has been the editor-in-chief of CRC Critical Reviews in Therapeutic Drug Carrier Systems since 2007. In 2010, he was a recipient of the FAMU Research Excellence Award. He has also worked for SynPhar Laboratories in Edmonton, in Alberta, Canada for four years as a group Leader for Drug Targeting. He has made significant contributions to the knowledge and understanding in the area of Drug Delivery with special emphasis in inhalation/aerosol delivery as applied to lung cancer and topical delivery of neuropeptides. Besides, Dr Sachdeva has identified new molecular pathways and mechanisms for therapeutic agents intended for the treatment of lung cancer and skin inflammation.

Kamalinder Singh

Professor, University of Central Lancashire

Dr. Kamalinder K Singh is Professor of Pharmaceutical Technology and Drug delivery at School of Pharmacy and Biomedical Sciences, University of Central Lancashire. After graduating from Panjab University, Chandigarh Dr. Kamalinder joined SNDT Women’s University, Mumbai in 1984 where she held various academic posts including Lecturer, Reader and Professor of Pharmaceutics and later was appointed to the position of Principal C. U Shah College of Pharmacy in 2010 to which she holds lien to. She has supervised 20 Ph. D students and ongoing research programmes focus on nanoparticulate drug delivery systems including protein based nanoparticles, lipid nanostructures, nanosuspensions, lipospheres, microspheres, taste masking and nanophytopharmaceuticals and span the following areas of development; pre-formulation; formulation development; physicochemical assessment; stability assessment and prediction; in-vitro performance tests, transport; pharmacokinetics and bio-distribution and in vitro-in vivo correlation. These drug delivery strategies are primarily being investigated for cancer, parasitic diseases and dermatological conditions either alone or in combination to prepare mixed nano-systems for delivery of single drug or co-delivery of multi-agents. She has special research interest in developing nanocarrier systems for targeting parasitized RBCs for effective treatment of malaria. She has a number of successful collaborations with other universities, and pharmaceutical industry leading to publications and development of new products and hold several patents in the pharmaceutical area.

Suresh P Vyas

Professor, Dr Harisingh Gour University

Prof. Suresh P. Vyas is a professor in the Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar, India. He has about 36 years of teaching and research experience at postgraduate level. He is pioneer scientist in the field of nano-biotechnology and immunology. He has judiously exploited bioligands for targeting of bioactives and antigens. He has supervised 51 PhDs and more than 130 M. Pharm students. He has over 315 research publications to his credit published in journals of high scientific impact. He authored 16 reference books including Pharmaceutical Biotechnology, Liposomal Therapeutics, Novel Controlled Drug Delivery Systems, Targeted Drug Delivery Systems, Theory and Practices in Novel Drug Delivery Systems and contributed many chapters in various renowned books. He is a commonwealth postdoctoral fellowship awardee and has worked under fellowship at School of Pharmacy University of London (U.K.). Prof. Vyas is a recipient of Best Scientist award by Association of Pharmacy Professionals (APP) 2014, National Teacher Excellence Award by IES group of Institution, 2014, Pandit Lajja Shankar Jha award, Best Pharmacy Teacher of the year 2001 by Association of Pharmaceutical Teachers of India and many more. He has been on various administrative positions of the university including Dean, Faculty of technology; Head, Department of Pharmaceutical Sciences and Department of Biotechnology, Chairman, board of studies etc. He serves on the editorial board of International Journal of Pharmaceutics (Elsevier), Recent Patents on Drug Delivery and Formulation (Bentham Science Publishers), Therapeutic Delivery (Future Science Groups), Journal of Drug Delivery (Hindawi) and Journal of Nanoscience Letters (Simplex publishers). Prof. Vyas is widely visited scientist and delivered invited/popular/keynote addresses in national and international conferences in India and abroad.